Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease
Summary
- Lipid effects of NNRTIs vary (Table 2)
- Efavirenz is associated with increases in TC and TG, although TC/HDL ratio generally remains unchanged[Young 2005]
- Efavirenz has been shown to have greater lipid effects than atazanavir/ritonavir[Riddler 2008; Daar 2011]
- Efavirenz is associated with increases in TC and TG, although TC/HDL ratio generally remains unchanged[Young 2005]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Dyslipidemia, Treatment Complications